Dressing for promoting wound healing and preparation method and application thereof

By using microwell array carrier technology in stem cell ball dressing, the stem cell balls are evenly distributed and the shelf life is extended, and the problems of uneven delivery of stem cell balls in the existing technology are solved, achieving efficient wound healing effect and clinical application. feasibility.

CN118903520APending Publication Date: 2024-11-08UNIV OF MACAU
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410927033.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently and evenly deliver 3D stem cell spheres to wound sites, and the shelf life is short at room temperature, making it difficult to meet the needs of clinical applications.

Method used

Using a carrier with a microwell array, stem cell suspension is added to the carrier, and stem cell ball dressing with good elasticity and skin fit is prepared through 3D printing and other technologies to ensure the activity and differentiation potential of stem cell balls, achieving uniform distribution and Long-term shelf life.

Benefits of technology

It achieves uniform distribution and efficient delivery of stem cell spheres, extends the shelf life to 6 days, ensures the activity and effectiveness of the dressing during transportation, and has great clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004938516500000071
    Figure BDA0004938516500000071
  • Figure HDA0004938516510000011
    Figure HDA0004938516510000011
  • Figure HDA0004938516510000012
    Figure HDA0004938516510000012
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and particularly relates to a dressing for promoting wound healing and a preparation method and application thereof. The present invention provides a composition comprising a carrier having an array of microwells, and a cell. The composition can be prepared into a customized stem cell sphere dressing, has good elasticity and skin fitness, can promote wound healing of a wound and accelerate wound recovery, and has a shelf life as long as 6 days at room temperature. In a mouse model, the dressing can promote cell proliferation and migration, perform immunoregulation through stem cell spheres, relieve inflammatory response, inhibit wound inflammation by secreting anti-inflammatory protein TSG-6 and IL-10 anti-inflammatory factors, induce wound angiogenesis and ordered collagen deposition, and promote wound remodeling and healing. The dressing obtained by the invention has huge clinical application value, and ensures the feasibility of the stem cell spheres from factory to clinical use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and specifically relates to a dressing for promoting wound healing and a preparation method and application thereof. Background Art

[0002] Skin is the largest organ in our body and is the frontline defender of the human body. However, wounds often occur due to various reasons. When the skin is severely damaged by factors such as trauma, the body's internal balance will be broken. Wounds must be treated in time, otherwise they may cause infection, a series of complications, and even death. The wound treatment steps generally include cleaning the wound, disinfecting the wound, and covering the wound with a dressing. The dressing plays a decisive role in wound healing.

[0003] In recent years, regenerative medicine has proposed novel high-tech dressing designs, and cell therapy has also received widespread attention as an effective treatment method. Cell therapy can improve wound healing without major surgery and skin graft donation. Recent studies have shown that mesenchymal stem cells (MSCs) benefit from paracrine signaling and low immunogenicity and are very promising as an allogeneic source for accelerating wound healing. Exogenously implanted MSCs participate in wound repair mainly by differentiating into skin cells and acting paracrine. It secretes a variety of bioactive factors that help wound healing, such as vascular endothelial growth factor, epidermal growth factor, angiogenin, interleukin 6, transforming growth factor-β, regulatory peptides, stem cell-specific homing and trophic factors, etc. It can promote angiogenesis and wound healing, and improve the symptoms of related complications. MSCs can also perform immunomodulation and inhibit wound inflammation by secreting anti-inflammatory proteins TSG-6 and IL10 anti-inflammatory factors. However, the delivery of mesenchymal stem cells to the wound site and ensuring the activity, paracrine and differentiation potential of mesenchymal stem cells still face considerable problems.

[0004] To solve this problem, various types of materials and technologies have been developed to better deliver mesenchymal stem cells to wounds. For example, scaffolds or hydrogel dressings of extracellular matrix (ECM) can be used as carriers for delivery. But this technology has limitations because the mesenchymal stem cells here are cultured in two dimensions (2D), and the paracrine effect of three-dimensional (3D) stem cell spheres is stronger than that of traditional 2D cells grown by adherent growth. Compared with traditional adherent-cultured mesenchymal stem cells, 3D-cultured stem cell spheres significantly enhance multiple biological functions such as anti-apoptosis, paracrine, multi-lineage differentiation, and anti-inflammation. In addition, 2D cells have a very short shelf life at room temperature, while 3D stem cell spheres retain more than 90% of their viability even after being placed at room temperature for 7 days.

[0005] To solve these problems, Wang Xiaoyan and others explored the manufacture of 3D stem cell spheres and dripped the stem cell spheres directly onto the wounds of mice, which is an effective, safe and non-invasive method to promote wound healing. The survival rate and paracrine function of 3D stem cell spheres were shown to be superior to 2D cell suspensions. However, it would be difficult for clinical patients to use this technology directly because the stem cell spheres here are delivered with laboratory pipettes and are difficult to package into convenient products for patients without laboratory work experience. Subsequently, alginate or other hydrogel encapsulation methods were developed to apply stem cell spheres to wounds as ointments, which are easy to change shape and adapt to the human body. Hydrogels are biomaterials that can promote the growth, proliferation and differentiation of mesenchymal stem cells by providing moisture and suitable conditions, thereby promoting wound healing and reducing scars. However, these methods are limited because most of the stem cell spheres carried by hydrogels are produced by the hanging drop method, which is labor-intensive and time-consuming. Although they successfully deliver stem cell spheres to wounds, these methods will result in uneven distribution of stem cell spheres in the wound, which will bring uncertainty to the entire healing process. Although alginate encapsulation can extend the shelf life of mesenchymal stem cell spheres to 3 days at 15°C while retaining their normal functions, it still cannot meet the requirements for room temperature storage. Therefore, there is still an urgent need to develop a 3D stem cell sphere-based dressing that can produce stem cell spheres in high yield, evenly distribute the stem cell spheres on the wound, and make the carrier easy to remove after the function is exerted, and it is easy to achieve multiple administrations without causing secondary skin damage, and has a certain shelf life to ensure that the dressing remains active during transportation from the factory to the hospital. Summary of the invention

[0006] The first aspect of the present invention aims to provide a composition.

[0007] The purpose of the second aspect of the present invention is to provide a method for preparing the composition of the first aspect of the present invention.

[0008] The third aspect of the present invention aims to provide a dressing.

[0009] The fourth aspect of the present invention aims to provide an application.

[0010] In order to achieve the above-mentioned purpose of the present invention, the technical solution adopted by the present invention is:

[0011] The first aspect of the present invention provides a composition comprising a carrier having a microwell array and cells.

[0012] The micro-well array consists of a plurality of micro-wells.

[0013] Preferably, the micro-well comprises a bottom surface and an opening.

[0014] Preferably, the bottom surface is one of circular, elliptical or polygonal.

[0015] Preferably, the bottom surface comprises a flat surface or a concave surface.

[0016] Preferably, the cells are located in microwells.

[0017] Preferably, the pore diameter of the micro-well is 300-1000 μm.

[0018] Preferably, the pore diameter of the micro-well is 300-900 μm.

[0019] Preferably, the pore diameter of the micro-well is 300-800 μm.

[0020] Preferably, the pore diameter of the micro-well is 400-600 μm.

[0021] Preferably, the depth of the micro-well is 450-1500 μm.

[0022] Preferably, the depth of the micro-well is 500-1000 μm.

[0023] Preferably, the depth of the micro-well is 600-900 μm.

[0024] Preferably, the depth of the micro-well is 700-800 μm.

[0025] Preferably, the ratio of the spacing between the micro-wells to their depth is 1:(1-5).

[0026] Preferably, the ratio of the spacing between the micro-wells to their depth is 1:(1-3).

[0027] Preferably, the ratio of the spacing between the micro-wells to their depth is 1:(1.5-2.5).

[0028] Preferably, the material of the carrier having the microwell array includes but is not limited to resin, silicone oil, alginate, hydrogel, or nanomaterial.

[0029] Preferably, the silicone oil comprises polydimethylsiloxane.

[0030] Preferably, the cells include but are not limited to mesenchymal stem cells.

[0031] Preferably, the mesenchymal stem cells are in the form of spheroids.

[0032] Preferably, the spheroid is specifically a cell in a suspended stretched state rather than a wall-attached morphology; the spheroid is not limited to a perfect sphere, and may also be an ellipsoid or an irregular shape that is shrunk due to other conditions such as water loss.

[0033] Preferably, the spheroid not only includes the morphology of a single cell, but also includes a plurality of spheroid cells aggregated to form a large stem cell sphere. In some embodiments of the present invention, a stem cell sphere with a diameter of 400 microns is composed of 24,000 stem cells.

[0034] The second aspect of the present invention provides a method for preparing the composition of the first aspect of the present invention, comprising the following steps:

[0035] 1) preparing a mold;

[0036] 2) mixing the material of the carrier and a curing agent and pouring them on a mold, and then performing inverting to obtain a carrier having a micro-well array;

[0037] 3) Add the cell suspension to the obtained carrier with the microwell array to obtain.

[0038] Preferably, the mold has a micro-column array; the micro-column array is composed of a plurality of micro-columns, and the tops of the micro-columns include but are not limited to circular, elliptical or polygonal shapes.

[0039] Preferably, the microcolumn has a diameter of 300 to 1000 μm.

[0040] Preferably, the height of the microcolumn is 450-1500 μm.

[0041] Preferably, the ratio of the spacing between the micro-pillars to their height is 1:(1-5).

[0042] Preferably, the size and height of the micro-pillars are compatible with the micro-wells in the composition of the first aspect of the present invention.

[0043] Preferably, the curing agent comprises at least one of all silane coupling agents including prepolymers with vinyl side chains and crosslinking agents.

[0044] Preferably, the preparation method of the mold includes but is not limited to 3D printing and photolithography. The ratio of the material of the carrier to the curing agent is (5-30):1.

[0045] Preferably, the material of the carrier is polydimethylsiloxane.

[0046] Preferably, the ratio of the polydimethylsiloxane to the curing agent is (10-20):1.

[0047] The third aspect of the present invention provides a dressing comprising the composition of the first aspect of the present invention.

[0048] Preferably, the dressing further comprises a pharmaceutically acceptable excipient.

[0049] Preferably, the auxiliary materials include but are not limited to viscous materials.

[0050] In some embodiments of the present invention, the adhesive material is 3M transparent dressing, and other conventional dressings can also achieve similar technical effects.

[0051] The fourth aspect of the present invention provides use of the composition of the first aspect of the present invention and the dressing of the third aspect in the preparation of a product that promotes wound healing.

[0052] The beneficial effects of the present invention are:

[0053] The present invention provides a composition, including a carrier with a microwell array, and cells. The composition can be prepared into a customized stem cell ball dressing, has good elasticity and skin conformability, can promote wound healing, accelerate wound recovery, and has a shelf life of up to 6 days at room temperature. In a mouse model, the dressing can promote cell proliferation and migration, perform immunomodulation through stem cell balls, reduce inflammatory response, inhibit wound inflammation by secreting anti-inflammatory proteins TSG-6 and il-10 anti-inflammatory factors, induce wound angiogenesis, orderly collagen deposition, and promote wound remodeling and healing. The dressing obtained by the present invention has great clinical application value, ensuring the feasibility of stem cell balls from factory to clinical use. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 The figure is a schematic diagram of the preparation and application process of the mesenchymal stem cell sphere (mesensphere)-based bandages (MBDs) of the present invention.

[0055] Figure 2 Schematic diagram of constructing microwell array templates with different aspect ratios for 3D modeling.

[0056] Figure 3 Schematic diagram of constructing microwell array templates with different diameters for 3D modeling. From left to right, the parameters of the four pillar arrays are 500μm diameter, 500μm pillar spacing; 400μm diameter, 400μm pillar spacing; 300μm diameter, 300μm pillar spacing; 200μm diameter, 300μm pillar spacing.

[0057] Figure 4The actual photographs of the Polydimethylsiloxane (PDMS) carrier with a micro-well diameter of 500μm, a depth of 750 microns, and a column spacing aspect ratio of 1:2. Among them, a is the actual picture and enlarged picture of the PDMS chip, where 4896 stem cell spheres can be clearly seen; b is the customized cutting of the PDMS chip into different shapes; c is the cut PDMS chip before being applied to the patient's foot model wound; d is the cut PDMS chip after being applied to the patient's foot model wound.

[0058] Figure 5 Cell viability and uniformity results of MBDs prepared with templates of different sizes.

[0059] Figure 6 The preparation and characterization results of the mesenchymal stem cell sphere bandage, where a is a template image made by a 3D printer; b is a photo of the PDMS chip peeled from the template and its cross-section and top view. The scale is 200μm; c is a representative fluorescent photo of stem cell spheres in a 500μm microwell; d is the uniformity result of stem cell spheres, with a scale of 500μm; e is the stability test of PDMS: the residual weight of PDMS in 0.25wt% trypsin and DMEM medium at room temperature, all experiments were repeated three times, and the data are reported as mean ± standard deviation; f is the PDMS biocompatibility test result, with a scale of 250μm; g is the SEM image of dense stem cell spheres in microwells, with a scale of 25μm; h is the PDMS elasticity and skin fit test results; i is the result of rapid migration and growth of stem cell spheres, and the live / dead staining of mesenchymal stem cell spheres after dissociation into suspended stem cells shows high vitality (n>10).

[0060] Figure 7 The results of stem cell activity of mesenchymal stem cell spheres after being stored at room temperature for different days.

[0061] Figure 8 Stem cell spheres accelerate wound healing simulated in vitro, where a is the secretion change of TGF-β1 over time; b is the secretion change of IL-10 over time; c is the scratch test results of human umbilical vein endothelial cells (HUVECs) under different culture conditions at 0 hours, 12 hours and 24 hours; d is the expression level of CD44, CD73, CD90 and CD105 of stem cell spheres, and homotypic staining was used as a control to subtract background fluorescence.

[0062] Fig. 9The in vivo wound healing evaluation results of MBDs, where a is a schematic diagram of the construction of the mouse incision splint model; b is a representative image of the wounds of mice with different treatments on days 0, 3, 4, 7 and 14; c is the wound tracking analysis result corresponding to b2; d is the percentage of the wound area of ​​mice after the transplantation of mesenchymal stem cell spheres and MSCDiss (dissocited mesenchymal stem cells).

[0063] Fig.10 The results of stem cell spheres staying on the wound surface, where a is a schematic diagram of the first MBDs treatment, b is a schematic diagram of the second MBDs treatment, c is the fluorescence result of stem cell spheres on the wound surface 5 days after treatment, and d is the fluorescence result of wound tissue sections 5 days after treatment.

[0064] Fig.11 The histological experimental results of the wound surface on the 14th day after the blank group, mesenchymal stem cell spheres (MBDs), and MSCdiss treatment, where a is the H&E staining result of the wound surface tissue of each group on the 14th day, the skin thickness is represented by the arrow length (left figure) (scale bar: 250μm), and the enlarged image of the epidermis calculation is represented by a pink arrow on the right (scale bar: 500μm). (Skin thickness: red arrow; epidermal thickness: pink arrow; regenerated dermal appendage: yellow arrow; b is the result of immunofluorescence staining, CD206 (red) (scale bar: 50 μm), iNOS (red) (scale bar: 50 μm), Col-I (red) (scale bar: 50 μm), α-SMA (green) (scale bar: 100 μm) immunostaining represents anti-inflammatory markers, pro-inflammatory markers, type I collagen and angiogenesis-related markers, respectively, and DAPI-labeled cell nuclei are all blue. The expression of CD206, iNOS, and type I collagen in each group was quantified by the average gray value, and the expression of α-SMA was quantified by the integrated density. DETAILED DESCRIPTION

[0065] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0066] Figure 1 The present invention shows a schematic diagram of the preparation and application process of the mesenchymal stem cell sphere (mesensphere)-based bandages (MBDs).

[0067] All experiments in this invention were authorized by the University of Macau, and the relevant animal experiments were approved by the Ethics Review Committee of the University of Macau (UMARE-012-2019).

[0068] Example 1 Parameter Optimization of PDMS Carrier

[0069] In this embodiment, a micro-well array template with different column heights and column spacings is constructed by 3D modeling. The diameters of the micro-wells include 200, 300, 500, and 700 μm, and the ratios of the heights and spacings include 1:2, 1:3, and 1:4. Figure 2 In addition, molds with a diameter of 500 μm, a column height of 750 μm, and a column spacing of 500 μm; a diameter of 400 μm, a column height of 600 μm, and a column spacing of 400 μm; a diameter of 300 μm, a column height of 450 μm, and a column spacing of 300 μm; and a diameter of 200 μm, a column height of 300 μm, and a column spacing of 300 μm were also constructed, as shown in FIG. Figure 3 shown.

[0070] The specific parameters of different templates are shown in Table 1.

[0071] Table 1 Specific parameters of different templates

[0072]

[0073] Printed using high-precision 3D printing resin (NanoArch S240, BMF Precision Tech, Inc.). The template was thoroughly cleaned with acetone and isopropanol and then blown dry. Then, polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, USA) was poured onto the template in a standard 15:1 ratio mixture of prepolymer and curing agent and cured at 65°C for 24 hours. The PDMS carrier was then carefully cut and peeled off from the template. Subsequently, the PDMS carrier was trimmed to the appropriate size using an art knife (OLFA, Japan). The PDMS carrier was sterilized with ultraviolet light and then rinsed with Phosphate buffer saline (PBS, ThermoFisher Scientific). The PDMS carrier was incubated with 2% Pluronic F127 overnight before use to help the PDMS surface enter a low adhesion state to facilitate spheroid formation. Remove the 2% Pluronic F127 before use and wash the PDMS carrier twice with PBS.

[0074] Figure 4This is a photo of a carrier with a microwell diameter of 500 μm, a depth of 750 μm, and a column spacing aspect ratio of 1:2. The picture has 68×72 microwells, a total of 4896. However, its length and width are less than 3 cm, indicating that the throughput of producing stem cell spheres using this carrier is very high. Those skilled in the art can cut the carrier according to the needs of actual applications to obtain the required size. The protection scope of the present invention is not limited to the scope recorded in this specification, and carriers of other sizes and microwell numbers should also be included in the protection scope of this technical solution.

[0075] Example 2 Preparation of PDMS-stem cell sphere chip

[0076] This embodiment uses mesenchymal stem cell lines (MSCs) and human intravenous endothelial cells (HUVECs) cell lines. MSCs are produced by inducing human embryonic stem cells (hESC) to differentiate into MSCs by the following method. First, hESCs are dispersed into a 6-well culture plate coated with Matrigel (BD Bioscience, San Diego, CA, http: / / www.bdbiosciences.com) and cultured overnight in mTeSR1 complete medium (Stemcell Technologies, Vancouver, BC, Canada, http: / / www.stemcell.com). Then, the spent culture medium is removed, and mTeSR1 Minus SelectFactors culture medium (Stemcell Technologies) is added in an amount of 2 ml per well, and 10 ng / ml BMP4 (Stemgent) and 1 μM A83-01 (Stemgent) are added at the same time. The cells are cultured at 37°C and 5% CO2 for 5 days. After 5 days of culture, TrypLE Gibco TMMSCs were obtained by digestion and dispersion. (Wang X, Lazorchak AS, Song L, et al. Immunemodulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage [J]. Stem cells, 2016, 34 (2): 380-391.). Such differentiated MSCs can express high levels of green fluorescent protein (M. Costa, et al., The hESC line Envy expresses high levels of GFP in all differentiated progeny, Nat. Methods 2 (2005) 259e260.). HUVECs c were cultured in a medium containing 10 v / v% fetal bovine serum (Gibco TM ,26140-079) in DMEM (Gibco TM ,11965092) culture medium. All experiments used MSCs between passages 6 and 10. MSCs were cultured in mesenchymal cell complete culture medium. Mesenchymal cell complete culture medium: containing 20 v / v% fetal bovine serum (Gibco TM ,26140-079) MinimumEssential Mediumα (Gibco TM ,12571-063), 1v / v% MEM NEAA (Gibco,11140-050), 1v / v% glutamate (Gibco,35050-061)max and 1v / v% penicillin-streptomycin (PS, Invitrogen). Renew every 2-3 days. Passage MSCs every 5-7 days. All cells were cultured in an incubator with 100% humidity and 5% CO2. In order to make MSCs form spheres, when MSCs reached 80% confluence, they were dissociated into cell suspension with 0.25wt% trypsin (Gibco,25200056), and then 1mL of cell suspension (cell concentration was about 1×10 7 / mL) into a PDMS carrier (prepared in Example 1, including carriers with different diameters, heights and spacing ratios).

[0077] Next, the PDMS chip was adhered to the centrifuge rotor and centrifuged at 800 rpm for 2 minutes (Eppendorf, 5810R), and the carrier was rinsed with PBS to remove excess cells. After adding 1 mL of cell culture medium to the PDMS carrier, the PDMS carrier was placed in a cell culture incubator and cultured for 48 hours. The stem cells will self-assemble into spheroids in the microwells. When used, a puncher was used to punch and cut specific areas of the PDMS chip containing the stem cell spheres, and 3M transparent adhesive dressings were glued to this specific area to obtain stem cell sphere bandages (Mesenchymal stem cell sphere (mesensphere)-based bandages, MBDs).

[0078] The uniformity of MBDs with different microwell diameters, heights and spacing ratios was tested. MBDs with 224 microwells were made for cell viability and uniformity testing. In MBDs, multiple stem cells can aggregate to form stem cell spheres. A stem cell sphere with a diameter of 400 microns can be composed of 24,000 stem cells.

[0079] in Figure 5 The results of the uniformity of the particle size distribution of stem cell spheres in MBDs with diameters of 200 μm and column spacings of 300 μm; diameters of 300 μm and column spacings of 300 μm; diameters of 400 μm and column spacings of 400 μm; and diameters of 500 μm and column spacings of 500 μm were respectively shown. After 48 hours of culture, the cell suspension self-assembled into stem cell spheres, and then photographed with a microscope (Nikon, Ti2). The pictures were processed with Image J software to obtain the diameter data of the stem cell spheres, calculate the statistical results, and draw a particle size distribution diagram. The results showed that the stem cell spheres obtained with different diameters and sizes had good uniformity, and the maximum coefficient of dispersion did not exceed 11.61%.

[0080] In subsequent experiments, MBDs with a microcolumn diameter of 500 μm, a height of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm were used as an example for experiments.

[0081] Example 3 Characterization of PDMS-stem cell sphere chip

[0082] The experiment was conducted using MBDs with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm. The template image produced by the 3D printer is shown in the figure. Figure 6 As shown in a, the PDMS carrier and its cross-section and top view are shown in Figure 6 As shown in b.

[0083] 1. Experimental methods:

[0084] 1) Cell viability assessment: Use a pipette to transfer the stem cell spheres from the PDMS carrier to a 60 mm culture dish. Add collagenase (10 mL Advanced DMEM / F12 containing 1x Glutamax, 10 mM HEPES, antibiotics and 2 mg / ml-1 collagenase (Sigma, C9407) to the culture dish to digest the stem cell spheres into single cells, and then use CalceinAM and Ethd-1 (LIVE / DEAD TM Viability / Cytotoxicity Kit Invitrogen TM , L3224) staining. Take pictures with a fluorescence microscope. Cell viability = live cells / (live cells+dead cells). In another method of evaluating viability, a pipette is used to transfer the stem cell spheres from the PDMS to a 60 mm culture dish. Then, sufficient mesenchymal cell complete culture medium of Example 2 is added, and the culture dish is placed in a cell culture incubator. Since the culture environment is converted from a low-adhesion microwell to a high-adhesion culture dish, the stem cell spheres formed by the aggregation of multiple mesenchymal stem cells will be released from the aggregation, and the mesenchymal stem cells will reattach to the wall and become spindle cells that grow on the wall. If the cells die, they will be round and unable to reattach to the wall. Therefore, most of the cells are able to reattach to the wall, indicating that the stem cell spheres have high activity. The culture medium contains 20 v / v% fetal bovine serum (Gibco TM ,26140-079) Minimum Essential Mediumα (Gibco TM ,12571-063), 1v / v% MEMNEAA (Gibco, 11140-050), 1v / v% glutamic acid (Gibco, 35050-061)max and 1v / v% penicillin-streptomycin (PS, Invitrogen)).

[0085] 2) Stability of PDMS

[0086] The PDMS carrier with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm prepared in Example 1 was placed in 0.25 wt % trypsin and DMED culture medium (Gibco TM ,11965092) and placed in a room temperature environment. Dry with a nitrogen gun and weigh with an electronic scale.

[0087] 3) Safety of PDMS

[0088] The PDMS carrier with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance-cross-section circle diameter) of 375 μm prepared in Example 1 was immersed in the above-mentioned mesenchymal cell complete culture medium and placed in a sterile environment at room temperature for 7 days. Then, MSCs were cultured in a cell culture incubator for 1 day with the leaching solution. Then, MSCs were stained with CalceinAM and Ethd-1 to observe their vitality. The mesenchymal cell complete culture medium that had not been immersed in PDMS was used as the control group.

[0089] 4) Scanning electron microscopy (SEM)

[0090] The stem cell spheres were fixed in the microwells of the PDMS carrier using 2.5v / v% glutaraldehyde fixative (SPI, 02607-BA) and stored in a 4-degree refrigerator for 24h. The fixative was removed and the sample was rinsed 3 times with 0.1M phosphate buffer at pH 7 for 15 minutes each time. The sample was then fixed with 1wt% osmium acid solution for 1-2h, the osmium acid waste liquid was carefully removed, and rinsed 3 times with 0.1M phosphate buffer PB (PH7.4) for 15 minutes each time. After that, the sample was dehydrated in a gradient manner, and dehydrated for 15 minutes at each concentration using a gradient concentration (30%, 50%, 70%, 80%, 90%, 95%, 6 concentrations) of ethanol solution (Sinopsin Chemical Reagent Co., LTD., 100092183), and then treated with 100% ethanol for 20 minutes. Finally, a new 100% ethanol was replaced and the sample was placed in 100% ethanol. The samples were then dried in a critical point dryer (Quorom k850, UK). The samples were fixed on the sample stage with conductive carbon glue and gold was sprayed for about 30 seconds using an ion sputtering device (Hitachi MC1000, Japan). The samples were then observed and photographed under a scanning electron microscope (Hitachi SU3050, Japan).

[0091] 2. Experimental results

[0092] The results of the activity test of the MBDs prepared in Example 2 with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm are as follows: Figure 6 As shown in c, the cell activity is normal and the cell uniformity is Figure 6 As shown in middle d.

[0093] The stability results of the PDMS carrier prepared in Example 1 with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm are as follows: Figure 6 As shown in middle e, the PDMS support is stable in trypsin or DMEM culture medium, with no weight change, and no swelling or shrinkage due to water absorption.

[0094] The safety results of the PDMS carrier prepared in Example 2 with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm are as follows: Figure 6 As shown in middle f, compared with the normal complete culture medium, there was no difference in the cell viability between the PDMS carrier leaching solution group and the control group, both close to 100%, indicating that PDMS has no toxic effect on MSCs.

[0095] The morphological structure of the stem cell sphere of MBDs prepared in Example 2 has a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm. Figure 6 As shown in middle g, the stem cell spheres in the MBDs have a compact and uniform structure.

[0096] The elastic test results of the MBDs prepared in Example 2 with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm are as follows: Figure 6 As shown in Figure 3, MBDs are very soft and flexible and can conform to the patient's skin in curved areas.

[0097] In order to determine the activity effect of MBDs, this example further explored the vitality of stem cell spheres. In this example, the stem cell spheres were first placed from MBDs into a common cell culture dish to observe whether the stem cell spheres could reattach to the culture dish ( Figure 6 In i, FF: Fluorescence field, BF: Bright field). Most cells can migrate from the aggregated stem cell spheres and reattach to the culture dish, indicating that the 200-500 μm-sized stem cell spheres have high vitality. On the other hand, after culturing for 48 hours under standard culture conditions (37°C, 5 v / v CO2%, 100% relative humidity), the stem cell spheres were removed from the PDMS chip and digested with collagenase for 6 hours into a cell suspension. The enzyme solution was 10 mL AdDF (Advanced DMEM / F12 containing 1x Glutamax, 10 mM HEPES, 1% v / v PS) containing 2 mg / mL 1 collagenase (Sigma, C9407).

[0098] Calcein / EthD-1 fluorescence staining was used to quantitatively analyze the viability of stem cell spheres. The number of live cells in the cell suspension after digestion accounted for the majority ( Figure 6 As shown in Figure 1, the survival rate of stem cell spheres of different sizes exceeded 94%. The two methods together showed that these stem cell spheres have very high activity, ensuring the feasibility of stem cell sphere bandages in playing a therapeutic role in wound healing.

[0099] Example 4 Shelf Life Detection of PDMS-Stem Cell Sphere Chip

[0100] 1. Experimental methods

[0101] Take the MBDs prepared in Example 2 with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm, and prepare multiple parallel MBDs. The MBDs are sealed in a tube filled with complete culture medium ( Figure 7 (as shown in a) and placed at room temperature (25°C) for 0-9 days. After being stored for different periods of time, the stem cell balls were transferred to a culture dish with a pipette and 3 ml of complete culture medium was added. The culture dish was placed in a cell culture incubator (Thermofisher) and cultured for 3 days. Pictures were taken with a microscope (Nikon, Ti2) to calculate the migration area of ​​MSCs after different shelf lives. The migration area of ​​the stem cell balls with a shelf life of 0 days was normalized to calculate the viability. The migrated live and dead cells were labeled with green and red fluorescence, respectively, and images were taken for analysis.

[0102] 2. Experimental results

[0103] In order to study the shelf life of stem cell spheres, in this example, the MBDs prepared in Example 2 with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm were sealed and placed at room temperature.

[0104] The results showed that the stem cell spheres maintained high viability during the 6-day shelf life, with rapid cell reattachment and migration, with a migration area of ​​at least 84% ( Figure 7 However, the viability of the stem cell spheres began to decline on the 7th day, with the migration area being only 25%, indicating a significant decrease in cell viability and migration ability. This downward trend continued until the 8th and 9th days. This may be attributed to the fact that the stem cell spheres entered a slow metabolic state in a hypoxic environment and began to run out of energy on the 7th day.

[0105] In summary, the results show that MBDs can be used in 6 days or less. The 6-day shelf life is valuable because it ensures the activity and effectiveness of MBDs during transportation to the hospital after production. The exploration of shelf life in this example can bring all stem cell sphere-based treatment strategies one step closer to true clinical application.

[0106] Example 5 PDMS-stem cell sphere chip promotes wound healing simulated in vitro

[0107] 1. Experimental methods

[0108] 1) ELISA to detect cytokine secretion

[0109] Take the MBDs with a microwell diameter of 500 μm, a depth of 750 microns, and a spacing (cross-section center distance-cross-section circle diameter) of 375 microns prepared in Example 2, and detect the secretion of cytokines on the 1st, 2nd, 3rd, 4th, and 5th day after the stem cell spheres are formed. 2D cells, that is, cells in traditional adherent culture, also collect supernatants after 1, 2, 3, 4, and 5 days, and store them at -80°C for further measurement of cytokine concentrations. After 1 day of adherent culture, the culture medium is collected and new culture medium is added, and the above operation is repeated for 2-5 days. In the 3D group (the group in which aggregated stem cell spheres are formed in MBDs), after the stem cell spheres are formed in PDMS, the old complete culture medium is removed and fresh complete culture medium is added. After 1 day, the supernatant is collected and stored at -80°C for further measurement of cytokine concentrations, and then fresh culture medium is re-added to the PDMS chip, and the above operation is repeated for 2-5 days. The concentrations of secreted cytokines (IL-10, Solebol, SEKH-0018 and TGFβ-1, Solebol, SEKH-0316) in the supernatant were measured using sandwich ELISA kits according to the manufacturer's instructions. The experiment was repeated three times (n = 3). The number of cells in each group was the same, regardless of whether it was in 2D monolayer culture or 3D spheroid culture, and each group contained 2.7 × 10 6 cells.

[0110] 2) Flow cytometry

[0111] Take the MBDs prepared in Example 2 with a micro-well diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance - cross-section circle diameter) of 375 μm, and add 3 mL of Trpsin-EDTA (0.25%, Gibco TM , 25200072) digested cells for 3 minutes to obtain a single cell suspension. Then, 3wt% bovine serum albumin (Beyotime, ST023) was used to block the cells for 0.5h at 4°C to ensure that the antibody can specifically bind to the target protein of the cell without binding to other proteins. Then, the primary antibodies (PE-CD44 and Cy5.5-CD105, BD Biosciences) were incubated on ice for 1 hour. Data were collected using a Cytoflex cytometer (Beckman Coulter) and analyzed using FlowJo software (Treestar).

[0112] 3) Scratch test

[0113] Conditioned medium (CM) was extracted from the cultured stem cell spheres for in vitro scratch test. The conditioned medium of the stem cell group was serum-free medium (αMEM, Gibco TM, 12571063) was added to MBDs containing 224 stem cell spheres (MBDs with a microwell diameter of 500 μm, a depth of 750 μm, and a spacing (cross-section center distance-cross-section circle diameter) of 375 μm prepared in Example 2 were cut into a size of 224 microwells), incubated for 7 days, and then the supernatant was collected. The control group only used serum-free medium (SFM-control). HUVECs were seeded in a 60 mm culture dish, and complete culture medium was added to the culture dish so that the cells 100% covered the culture dish. 16 hours before making the scratch, the complete culture medium was replaced with DMEM without FBS for serum deprivation to starve the cells. The monolayer of HUVECs was scraped with the tip of a 200 μL pipette to form a wound. After aspirating the culture medium and gently washing the cell debris, the cells were respectively treated with stem cell sphere CM (conditioned medium) and control group serum-free culture medium (αMEM, Gibco TM , 12571063) to replace the culture medium. The test samples (n = 3 per group) were stored in a humidified incubator with 5% CO2 at 37°C. The migration of HUVECs in the scratched area was photographed at 0, 12 and 24 h. The wound area was measured as follows: wound area (%) = 12 (or 24) h wound area / 0 h wound area × 100%.

[0114] 2. Experimental results

[0115] The secretion of two key cytokines during wound healing was measured by enzyme-linked immunosorbent assay (ELISA). Figure 8 As shown in a and b, compared with 2D culture, 3D culture of stem cell spheres can significantly promote the secretion of IL-10 and TGF-β1. During this period, the continuous production of these two cytokines is a decisive factor in promoting wound healing. The concentration of TGF-β1 is generally higher than that of IL-10. On the first day after the formation of stem cell spheres, the concentration of TGF-β1 secreted by stem cell spheres was the highest among all groups. The secretion of TGF-β1 in the 3D group on the first day was 10 times that of the 2D group, while the secretion of IL-10 was about 3 times, indicating that the effect of 3D culture on TGF-β1 secretion was more profound than IL-10. In the 2D and 3D groups, there was only a slight difference in the secretion of IL-10 at different times. During these 5 days, the secretion of IL-10 in the 3D group was about 3 times that of the 2D group. This shows that the secretion of IL-10 is relatively slow and stable. In this case, 3D culture also promotes the secretion of IL-10 cytokine compared with 2D culture. In addition, the 2D and 3D groups secreted most of these two cytokines on the fifth day, indicating that the cell viability in both 2D and 3D cultures did not decrease significantly.

[0116] Cell migration ability is another important factor in promoting wound healing. First, the conditioned medium (CM) for culturing stem cell spheres was prepared. 1 mL of serum-free medium (SFM) was added to MBDs containing 224 microwells, incubated for 7 days, and the medium was collected. The control group used SFM. After scratching and adding these two culture media, human umbilical vein endothelial cells (HUVECs) were cultured and photographed at 0, 12, and 24 hour intervals. At 12h and 24h, the wound healing area in the stem cell sphere group was 17.8% and 9.37% faster than that in the control group, respectively ( Figure 8 The above results confirm that the secretory products of MBDs can promote cell migration.

[0117] Mesenchymal stem cells can promote wound healing by differentiating into cells required for wound healing, so it is important to ensure that the mesenchymal stem cells maintain their differentiation potential after forming into spheres. To this end, this example uses flow cytometry to determine whether the stem cell spheres still retain MSCs markers. The results are shown in Figure 2. Figure 8 As shown in middle d, the stem cell spheres in MBDs are still strongly positive for MSC markers CD44, CD73, CD90, and CD105. These results indicate that the stem cell spheres in MBDs can secrete cytokines, promote cell migration, maintain cell stemness, differentiate into specific cell types, and directly participate in tissue repair.

[0118] Example 6 Stem cell spheres accelerate wound healing in vivo

[0119] 1. Experimental methods

[0120] This experiment used an immunodeficient nude mouse excisional wound splinting model (Wang X, Ge J, Tredget EE, et al. The mouse excisional wound splinting model, including applications for stem cell transplantation [J]. Nature protocols, 2013, 8 (2): 302-309.). Two full-thickness circular wounds with a diameter of 6 mm were prepared on both sides of the back. The animals were randomly divided into three groups: MBDs group, MSCDiss (dissocited mesenchymal stem cells) group and blank group. For the MBDs group, a total of two treatments (day 0 and day 1), once a day, the MBDs prepared in Example 2 with a microwell diameter of 500 μm, a height of 750 μm, and a spacing (cross-section center distance-cross-section circle diameter) of 375 μm were trimmed to a size matching the wound (i.e., a circular band-aid with 24 microwells), and fitted with the wound, equivalent to 1×106 MSCs were delivered to the wound surface. For MSCDiss treatment, the best combined method reported previously (Wang X, Ge J, Tredget EE, Wu Y. The mouse excisional woundsplinting model, including applications for stem cell transplantation. Nat Protoc. 2013; 8: 302-9.) was used to deliver 0.7×10 6 MSCDiss were resuspended in 100 μl PBS and injected evenly into four points around the wound surface (upper, lower, left, and right). 6 Each MSCDiss was mixed with 30 μL Matrigel (BD Bioscience, San Diego, CA, http: / / www.bdbiosciences.com ) were mixed evenly and then dropped on the wound surface. The blank group was not treated. The skin tissues were observed on days 0, 4, 7, and 14, and tissues were collected on day 14. The full-thickness skin tissues were collected and preserved in paraformaldehyde fixative for hematoxylin and eosin (HE) staining, iNOS (Abcam), CD206 (Abcam), α-SMA (Biolegend), and Col-I antibody (Abcam) immunofluorescence staining to evaluate the inflammatory state, neovascularization, and collagen formation. The average relative fluorescence density of IF staining was calculated using Image J software.

[0121] 2. Experimental results

[0122] In vivo experimental procedures Fig. 9 As shown in Figure a. MBDs can be firmly fixed on the wound surface. After the MBDs treatment was completed (day 2), the MBDs were removed to reduce inflammation. On day 4 after treatment, there was no significant difference in wound healing among the three groups. By day 7, the wound healing rate in the MBDs group was accelerated compared with the MSCDiss and blank groups, which became more obvious on day 14 (as shown in Figure 2). Figure 8 According to the statistics of wound morphology and wound area, the wound healing effect of the MBDs treatment group was the best (e.g. Figure 8 On day 14, the healing rate was increased by 33% and 18% compared with the blank group and MSCdiss group, respectively.

[0123] In order to ensure that the stem cell balls have successfully landed on and entered the wound, this example further uses in vivo sample slice imaging to detect the signal of the stem cell balls. MSCs are transfected with green fluorescent protein and show green fluorescence under 488nm excitation. The results are shown in Figure 2. Fig. 9As shown in a and b, it can be clearly observed with the naked eye that the stem cell spheres have fallen onto the wound after one administration, and the same is true after two administrations.

[0124] Five days after treatment, the stem cell spheres could still be seen entering the wound and still had strong green fluorescence, further indicating that the delivered stem cell spheres could stably enter the dermis around the wound surface ( Fig.10 In order to further prove that the stem cell spheres entered the wound, wound tissue sections were made 5 days after treatment. Fig.10 As shown in middle d, strong green fluorescence can be observed, proving that the stem cell spheres have entered the wound and maintained cell viability.

[0125] The above results indicate that MBDs have excellent wound healing properties and good adaptability to wounds of various shapes, and have great clinical application value.

[0126] Example 7 Histological evidence shows that MBDs promote wound healing

[0127] 1. Experimental Methods

[0128] 1.1 Hematoxylin-eosin staining (H&E)

[0129] Fresh wound tissue from mice was carefully and evenly placed on a piece of filter paper and fixed overnight at 4°C in a freshly prepared solution of cold 4% (wt / vol) paraformaldehyde (Sigma, cat.no.158127) in PBS (Sigma, cat.no.D5652). The sample should be immersed in the fixative. The next day, the tissue was moved to a 5 cm diameter tissue culture plate and washed five times with PBS on a shaker for 30 minutes each. The tissue was incubated in 20% and 40% (wt / vol) sucrose in PBS for 2 hours at room temperature. The tissue was embedded in Optimal cutting temperature (OCT) compound (Allegiance, cat.no.M7148-4). First, a small amount of OCT was added to the bottom of the freezing mold. The cut edge of the tissue was facing the bottom of the freezing mold. Fill the freezing mold with OCT compound. 6-micron thick frozen sections were cut on a freezing microtome and mounted on SuperFrost Plus slides (Fisher Scientific, cat.no.12-550-15). The wound tissue sections were washed with PBS to remove OCT; the sections were stained with H&E (Beyotime, C0105S, C0105M) and examined under an optical microscope. Wound photos near the wound edge were taken, and image software such as ImageJ was used to measure wound skin thickness and the number of skin appendages.

[0130] 1.2 Immunofluorescence staining

[0131] The above experimental steps were repeated and after the SuperFrost Plus slides with tissue were prepared, the tissue sections were washed with PBS to remove OCT, and then the sections were incubated with PBS containing 1 mg / mL sodium borohydride (Sigma, cat. no. 452882) for 30 minutes to reduce autofluorescence. The sections were blocked with PBS containing 5% (wt / vol) BSA (Sigma, cat. no. A2058) for 2 hours at room temperature. Next, they were incubated with specific primary antibodies against target proteins (iNOS, CD206, α-SMA, and Col-I antibodies) in PBS containing 1% (wt / vol) BSA overnight at 4°C. The next day, the tissue sections were washed three times with PBS. The sections were incubated with appropriate secondary antibodies for 1 hour at room temperature in the dark. After three PBS washes, the cell nuclei were stained with 10 μM Hoechst (Sigma, cat. no. B1155) in PBS for 5 minutes and the sections were observed under a microscope.

[0132] 2. Experimental results

[0133] During the skin wound repair process, local fibroblasts secrete extracellular matrix proteins, mainly collagen and fibronectin, to form newly formed granulation tissue, inducing the restoration of the structural integrity of the wound surface. Fig.11 As shown in middle a, the healing process in the MBDs-treated group was significantly accelerated, and tissue generation and reconstruction were easier. Consistent with the wound area tracking analysis, the skin thickness and the number of skin appendages in the MBDs-treated group increased. In addition, the epidermal thickness of the regenerated skin in the MBDs group was thicker, indicating that wound healing may have entered the remodeling stage. It is worth noting that the number of new blood vessels in the MBDs group (green arrows) was much higher than that in the MSCDiss group and the blank group. These findings provide convincing evidence for the overall therapeutic effect of MBDs in promoting wound repair. The deposition and arrangement of collagen in regenerated skin tissue are important indicators for evaluating the quality of wound healing. Immunofluorescence staining such as Fig.11 As shown in middle b, the expression of type 1 collagen in the MBDs group was higher than that in the MSCDiss group and the blank group. The above results suggest that MBDs can promote collagen deposition and correct the abnormal state of collagen fiber deposition.

[0134] Inflammatory response is an important component in promoting wound healing, because white blood cells can protect the wound from infection, but long-term inflammation can lead to delayed wound healing and even tissue damage. Therefore, the present invention detected the anti-inflammatory marker CD206 and the pro-inflammatory marker iNOS of macrophages in each group by immunofluorescence staining on the 14th day. The expression of CD206 was higher in the MSCDiss group and the MBDs group, thereby reducing the inflammatory response of the wound. It is worth noting that it was even higher in the MSCDiss group, which may be due to the high concentration of free mesenchymal stem cells. The expression of iNOS was lower in the MBDs group, which means that the wound healing stage is more stable and there is less chance of inducing inflammation.

[0135] α-SMA immunofluorescence staining was used to further analyze the angiogenesis of the wound surface. Fig.11 As shown in middle b, MBDs had more newborn and mature blood vessels than MSCDiss and the blank group. The results were consistent with the results of H&E staining. The high-density vascular system can deliver sufficient oxygen and nutrients to the wound site, which is beneficial to cell proliferation, cell migration, and metabolic activities related to wound healing.

[0136] In summary, MBDs regulate immunity by delivering intercellular globules, reduce inflammatory responses, inhibit wound inflammation by secreting anti-inflammatory proteins TSG-6 and IL-10 anti-inflammatory factors, induce wound angiogenesis, orderly collagen deposition, and promote wound remodeling and healing.

Claims

1. A composition, characterized in that comprising a carrier having a microwell array, and a cell; The micro-well array is composed of a plurality of micro-wells; The micro-well comprises a bottom surface and an opening; The bottom surface is one of a circle, an ellipse or a polygon; The bottom surface includes a flat surface or a concave surface; The cells are located in microwells; and / or The pore size of the microwell is 300-1000 μm; and / or The depth of the microwell is 450-1500 μm; The ratio of the spacing between the micro-wells to their depth is 1:(1-5).

2. The composition according to claim 1, characterized in that: The pore size of the microwell is 300-900 μm; and / or The depth of the micro-well is 500-1000 μm.

3. The composition according to claim 2, characterized in that: The material of the carrier having the microwell matrix includes, but is not limited to, resin, silicone oil, alginate, hydrogel, or nanomaterial; Preferably, the silicone oil comprises polydimethylsiloxane.

4. The composition according to claim 3, characterized in that: The cells include, but are not limited to, mesenchymal stem cells.

5. The composition according to claim 4, characterized in that: The mesenchymal stem cells are in the form of spheroids.

6. A method for preparing the composition according to any one of claims 1 to 5, comprising the following steps: 1) preparing a mold; 2) mixing the material of the carrier and a curing agent and pouring them on a mold, and then performing inverting to obtain a carrier having a micro-well array; 3) Add the cell suspension to the carrier with the microwell array to obtain.

7. The preparation method according to claim 6, characterized in that: In the step 2), the curing agent includes a silane coupling agent; The ratio of the carrier material to the curing agent is (5-30):1; Preferably, the material of the carrier is polydimethylsiloxane; Preferably, the ratio of the polydimethylsiloxane to the curing agent is (10-20):

1.

8. A dressing comprising the composition according to any one of claims 1 to 5.

9. The dressing according to claim 8, characterized in that: The dressing further comprises a pharmaceutically acceptable excipient; Preferably, the auxiliary material comprises a viscous material.

10. Use of the composition according to any one of claims 1 to 5 or the dressing according to claim 8 in the preparation of a product that promotes wound healing.